initial assay method (radioimmunoassay) to quantify pituitary gonadotrophins in serum was replaced approximately 5 years The immunoreactivity of various LH and FSH calibration ago by enzyme-linked immunoassays (EIA). The change in standards and recombinant preparations in the enzymethe assay methodology has brought about some numerical linked immunoassay (EIA) systems for gonadotrophins differences in assay results. For example, in the 1994 WHO developed for the Special Programme of Research in external quality assessment programme report, the ELISA Human Reproduction of the World Health Organization results were, on average, numerically 30% lower for LH, while (WHO) were compared. The preparations tested included those obtained for FSH were 50% higher (WHO Technical three LH and two FSH pituitary standards (calibrated Report, 1994) . Among the reasons for these numerical discrepagainst LH 80/552 and 68/40 and FSH 78/549 respectively) ancies are the use of different antibodies (e.g. polyclonal provided with the EIA or radioimmunoassay WHO antibodies in the radioimmunoassays versus monoclonal antimatched reagent kits, the pituitary preparation LER-907, bodies in the EIA) possessing distinct epitope specificities as and recombinant human LH (rhLH) and FSH (rhFSH).
well as the use of different pituitary preparations for conSimultaneous curve fitting of the EIA dose-response curves structing the standard curves, which may be differentially revealed no significant differences among the slopes generrecognized by a determined set of antibodies, particularly by ated by the WHO LH standards and LER-907; in contrast, those of monoclonal origin  Petterson no parallelism was found between the curves of rhLH and Soderholm, 1991; Vermes et al., 1991; Jeffcoate, 1993 ; and the pituitary-derived LH standards. No significant Costagliola et al., 1994a,b,c; Martin-Du-Pan et al., 1994 ; differences were found among the slopes of the curves Taylor et al., 1994) . In fact, significant variations in molecular elicited by the pituitary and recombinant FSH preparations. composition (mainly determined by the sample source, type Each LH preparation exhibited a high degree of charge of particular oligosaccharide chains attached to the protein heterogeneity. Considerable variations in charge isoform core of the molecule and purification methods used to isolate distribution among the WHO LH standards, rhLH and the glycoproteins) have been detected among some of the LER-907 were also evident. In contrast, the FSH preparahighly purified pituitary gonadotrophin preparations employed tions were less heterogeneous and exhibited minor differto calibrate the kit standards, which may be distinctly recogences in charge distribution. Despite the existing differences nized by antibodies and cognate receptors (Chappel et al., in charge isoform distribution, all the pituitary-derived 1986; Simoni et al., 1993; Chappel, 1995; Burgon et al., 1997 ; preparations as well as rhFSH seem appropriate for using Lambert et al., 1998) . Further, it has been shown that the as calibration standards in this particular EIA system. gonadotrophin glycoforms contained in crude pituitary extracts Key words: enzyme-linked immunoassay/FSH/LH and recombinant preparations may be either equally or differentially identified depending on the particular antibody configuration of the immunoassay system employed for their quantitative Introduction estimation (Zambrano et al., 1996; Oliver et al., 1999) .
In the present study, we analysed the dose-response curve Twenty five years ago, the Special Programme of Research, Development and Research Training in Human Reproduction, profiles of various widely employed pituitary and recombinant gonadotrophin preparations in the EIA system provided by the World Health Organization (WHO), established a validation, standardization and distribution programme to provide a num-WHO Programme for the Provision of Matched Assay Reagents for the Immunoassay of Hormones (henceforth: the prober of laboratories with reagents, the so-called matched reagents, for the assay of reproductive hormones in serum, gramme), and established their relative potency in this particu-protein), the LER-907 preparation as the standard and anti-human lar immunoassay. In addition, the behaviour of each preparation FSH-6 at final dilution of 1:250 000, as the antiserum (Timossi et al., in the EIA system was correlated with its particular molecular 1998). This antiserum exhibits less than 0.1% cross-reactivity with composition as revealed by preparative chromatofocusing.
highly purified human LH and prolactin and undetectable reactivity with free α-subunit and GH. In both radioimmunoassay systems, all LH and FSH isoforms displaced either 125 I-labelled FSH or LH from
Materials and methods
the antibody in a parallel fashion when tested at seven to 10 different Standards dilutions; in fact, simultaneous curve fitting of the dose-response The human LH preparations tested in this study were the partially curves revealed no significant differences among the slopes generated purified LER-907 standard for radioimmunoassay of gonadotrophins by FSH and LH present in the LER-907 standard and concentrated [obtained from the National Institute of Diabetes and Digestive pools of the several isoforms fractionated by chromatofocusing and Kidney Diseases (NIDDK) through the National Hormone and (Zambrano et al., 1996) (Storring et al., 1978) . For FSH, the following were phosphate (0.01 mol/l) buffered physiological (0.15 mol/l) saline, tested: the LER-907 standard, highly purified recombinant human FSH transferred to dialysis membrane tubing (molecular weight cut-off, (rhFSH) produced by CHO cells (ORG 32489; Organon International) 12 000-14 000; Spectrum Medical Industries, Los Angeles, CA, (Olijve et al., 1996) , a FSH standard preparation (WHO INEN) USA), dialysed at 4°C for 24 h against deionized water and thereafter provided by the WHO Collaborating Center in Cuba and calibrated against 0.01 mol/l ammonium carbonate (pH 7.5) and freeze-dried. against the WHO IRP of FSH 78/549 (Storring and Gaines Das, Lyophilates were redissolved to one tenth of original volume in 1989), and the FSH standard (coded herein as WHO 78/549C) Pharmalyte pH 8-10.5-HCl (Pharmacia Biotech, Piscataway, NJ, contained in the FSH EIA kit provided by the programme, which has USA) (1:45 dilution in deonized water, pH 7.0) and the suspension been calibrated against the WHO IRP 78/549.
was then applied to the top of a 30ϫ1 cm column of polybuffer exchange resin (PBE-118, Pharmacia Biotech), previously equilibrated Immunoassays of LH and FSH for 18-24 h with 25 mmol/l triethylamine-HCl, pH 11.0, and chromatoEnzyme-linked immunoassays focused at 4°C. Eluate fractions (2 ml each) were collected at a flow The EIA of LH and FSH were performed employing reagents provided rate of 1 ml/4 min. The pH of each fraction was then measured, and by the WHO Collaborating Centre for Research and Reference when a limiting pH of 7.0 had been reached the eluent buffer Services in the Immunoassay of Hormones in Human Reproduction, (Pharmalyte-HCl) was changed by Polybuffer-74 (Pharmacia Biotech) London UK, following the instructions provided by the centre. The diluted 1:8 in deionized water, pH 4.0, to elute proteins bound at assays were of an immunometric ('sandwich') design and employed pH 7.0-4.0. Proteins bound at the lower limiting pH (pH Ͻ3.50; salt two anti-LH or anti-FSH monoclonal antibodies. In each EIA, the peak) were finally recovered by the addition of 1.0 mol/l NaCl to the first antibody was directed against the β-subunit of the molecule and chromatofocusing column. The pH of each fraction was neutralized was attached to a magnetic particle, whereas the second antibody to pH 7.0 by the addition of either 200 µl 1.0 mol/l triethylaminewas directed against the α-subunit, and was labelled with alkaline HCl pH 7.0 (to those fractions with an elution pH value of 11.0 to phosphatase. These LH and FSH EIA systems exhibit ഛ0.1% and 7.0) or 1.0 mol/l imidazole-HCl pH 7.4 (to fractions recovered within 0.03% cross-reactivity with highly purified FSH and LH respectively, elution pH values of 6.99 to Ͻ4.0). Each fraction was stored frozen and undetectable reactivity with growth hormone (GH) and prolactin.
at -20°C until the day of the LH or FSH radioimmunoassays. All The intra-and interassay variables were ഛ4.0% and ഛ8.0% respectfractions from a single column were assayed in duplicate incubations ively. Results are expressed as ng or mIU as appropriate according in the same radioimmunoassay run. Recoveries of immunoactive LH to the particular standard preparation analysed.
and FSH after chromatofocusing were 75 Ϯ 5% of the total amount applied to the columns. Each gonadotrophin preparation was chromaRadioimmunoassays tofocused in three separate runs. The radioimmunoassay of LH was performed employing 125 I-labelled LH-I3 as the tracer (specific activity 70-90 µCi/µg protein), the Statistical analysis reference preparation LER-907 as the standard and the antihuman LH-3, at a final dilution of 1:800 000, as the antiserum (Ropelato Tests for parallelism among the slopes generated by the different gonadotrophin preparations in the EIA and the LH radioimmunoassay et al., 1999). Cross-reactivity of this antiserum with highly purified FSH, GH and prolactin is Ͻ0.2%. The sensitivity of the assay was were performed following the method of DeLean et al. (1978) . This method allows for simultaneous fitting and analysis of families of 0.7 IU/l. The FSH radioimmunoassay was performed employing 125 I-labelled FSH I-1 as the tracer (specific activity 60-70 µCi/µg sigmoidal dose-response curves and describes the curves in terms of basal and half maximal responses (ED 50 ) and curve shape or steepness. Relative potencies among the various preparations were calculated considering multiple points comprising the ED 20 -ED 80 interval. the 68/40C, WHO INEN and 80/552C standards respectively; n ϭ 6 EIA runs for each standard) and LER-907 (mean slope value 1.25 Ϯ 0.07; n ϭ 6). On the contrary, no parallelism was found between the curves generated by rhLH (mean slope value, 0.72 Ϯ 0.08) and the WHO and LER-907 LH standards. This finding contrasted with the dose-response curve elicited by rhLH in the polyclonal antibodies-based radioimmunoassay, which was parallel with that of the LER-907 standard ( Figure  2 ). The relative potency of each preparation tested in this LH EIA system is shown in Table I . The potency of LH contained in the WHO INEN standard was slightly higher than that of the WHO 80/552C standard and lower than that yielded by WHO 68/40C; the immunopotency of these two latter standards was nearly the same. According to this EIA system, the potency of the WHO standards was similar when expressed in terms of the LER-907 preparation and vice versa.
EIA of the FSH preparations
Representative dose-response curves elicited by the two WHO FSH standards, LER-907 and rhFSH, in the FSH EIA system response curves revealed no significant differences among the slopes generated by the various preparations tested (mean tions showed variable amounts of LH and FSH immunoactivity slope values: 1.05 Ϯ 0.05, 1.07 Ϯ 0.06, 1.04 Ϯ 0.04 and in fractions corresponding to molecules bound at the lower 1.12 Ϯ 0.03, for the 78/549C, WHO INEN, rhFSH and limiting pH, which were recovered after the addition of a LER-907 standards respectively; n ϭ 6 EIA runs for each highly concentrated NaCl solution to the chromatofocusing preparation). On a weight-to-weight basis, rhFSH was approxicolumn (salt peak). As depicted in Figure 4 , the WHO 68/40C mately four times more potent that LER-907; the immunopotand 80/552C LH kit standards exhibited very similar charge ency of the FSH 78/549C kit standard was slightly higher than distribution profiles; both standards contained negligible that of the WHO INEN standard when compared on a unitamounts (Ͻ3% of the total LH recovered) of LH molecules to-unit basis (Table II) .
within the salt peak. In contrast, the WHO INEN, rhLH and LER-907 preparations presented a higher (6-16%) content of Chromatofocusing of the LH and FSH standards and prethis strongly acidic LH species. Although the bulk (71-75% parations of total) of LH immunoreactivity in the WHO INEN standard Figures 4 and 5 show the pH distribution pattern of immunoand rhLH preparation was recovered at pH values Ͻ7.0, reactive LH and FSH after chromatofocusing of the various significant amounts of immunoactivity (15-22% of total) were preparations analysed. As shown, each preparation contained additionally detected at higher pH values; in fact, these two two or more charge isoforms recovered within a pH window preparations presented the highest degree of charge heteroof 9.0 to 3.50 and 6.50 to 3.50 for the LH and FSH containing geneity (in terms of total number of LH components resolved preparations respectively. In addition, all standards and preparaby the charge-based separation technique employed). In general, LH contained in LER-907, rhLH and WHO INEN was more acidic than that present in the remaining WHO LH In the chromatofocusing system employed (pH window from 10.0 to Ͻ3.5), the bulk (Ͻ80% of total) of were similar; both preparations exhibited a single broad FSH peak with a median pH value of 4. 53-4.60 and a et al., 1990; Harris et al., 1998) . Several lines of evidence indicate that differences in glycosylation may affect the reactivsecond large component recovered within the salt peak.
ity of glycoprotein towards certain antibodies (Papandreou et al., 1990 (Papandreou et al., , 1991 Labbe-Jullie et al., 1992; Zerfaoui and Discussion Ronin, 1996) . For example, removal of sialic acid from Analysis of the dose-response curves of several LH standards pituitary thyrotropin specifically abolished the binding of this and preparations in the EIA system, developed for the WHO natural glycoprotein to anti-β monoclonal antibodies (Zerfaoui Special Programme of Research in Human Reproduction, and Ronin, 1996) and its deglycosylation led to a five-fold revealed a close similarity among the curves elicited by reduction in immunoreactivity toward certain anti-β polyclonal the WHO LH 68/40C, 80/552C and INEN standards. This antibodies (Papandreou et al., 1990) . In the present study, the agreement in dose-response curve profiles among the various behaviour of rhLH in the WHO EIA contrasted with that WHO LH standards tested was in marked contrast with that exhibited in the radioimmunoassay, in which rhLH displaced exhibited by the rhLH preparation produced in CHO cells, 125 I-labelled LH from the antibody in a fashion similar to whose absence of parallelism with the that shown by the pituitary-derived LER-907 standard, thus curves was clearly noticeable. The non-parallelism exhibited emphasizing the importance of the particular antibody configby this particular preparation may be due either to vulnerability uration employed for determining the immunoreactivity of to matrix effects at low doses or to differences in molecular recombinant DNA-derived preparations. The overall data indispecificity of the matched monoclonal antibodies employed in cate that recombinant human LH produced by CHO cells is this EIA system for the mixture of rhLH glycoforms contained not a suitable preparation for use as the calibration standard in this particular preparation and that of the naturally occurring in this particular monoclonal antibody-based EIA system and variants present in the preparations of pituitary origin. In that all other WHO LH standard preparations tested may be fact, several differences in glycosylation exist between rhLH indistinctly employed without significant variations in the final produced by CHO cells and pituitary LH: oligosaccharides in concentration results of the unknown samples. CHO cell-derived gonadotrophins are sialylated only in an α2-In contrast to the set of LH preparations tested in the 3 conformation, do not contain bisecting N-acetyl glucosamine EIA system, the dose-response curves elicited by both the moieties and sulphated terminal glycosylation is missing (Hård recombinant and pituitary FSH preparations were parallel to et al ., 1990; Rafferty et al., 1995; Amoresano et al., 1996;  each other. Thus, differences in glycosylation between the Talbot et al., 1996) . In addition, it is known that CHO CHO cell-derived preparation and the pituitary standards did cells have a limited ability to introduce complex branched not apparently influence to a considerable extent the reactivity carbohydrate structures onto the protein core in comparison of the former preparation toward the set of monoclonal antibodies employed in this FSH EIA system. Although the with the naturally producing cells, the gonadotrophs (Hård present study does not unambiguously resolve whether the parallel to each other across a wide range of concentration values. Although variations in purity and concentration units monoclonal antibodies employed reacted equally with all FSH preparations tested, the profile of the dose-response curves of the various gonadotrophin preparations do not allow accurate establishment of the exact degree of cross-reactivity of the elicited by the four preparations indicates that all preparations may be used as calibration standards at least in this particular monoclonal antibodies employed in these EIA kits toward the standards tested, all the pituitary-derived preparations as well human FSH EIA.
All LH preparations exhibited a high degree of charge as rhFSH produced by CHO cells seem appropriate for using as calibration standards in this particular immunometric system. heterogeneity. In particular, the pH distribution profile exhibited by rhLH, LER-907 and the WHO INEN LH preparations was
The impact of the differences in mixture of gonadotrophin isoforms between these particular preparations and the human more acidic than that of the WHO 68/40C and 80/552C standards; these differences may be due to selective removal serum on the accuracy of measurements of LH and FSH in serum samples by this and other immunometric assay systems of the more or less basic isoforms during the purification procedures as well as to cell-specific (gonadotrophs and CHO is an issue that deserves to be scrutinized carefully. cells) particularities in post-translational processing of the gonadotrophin molecule (Ulloa- Aguirre et al., 1995a) . Interes
